Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product...(brands stated John P. McLaughlin chief ...)

In related news, James Z. Huang has relocated to the east coast for personal reasons and will transition to a consulting role from his position as president. Mr. Huang, who joined Anesiva in September 2002 as vice president, business development & commercial operations, will remain very involved in the company's commercialization efforts.

During the meeting, Anesiva will review many parallel activities currently underway to prepare the market for Zingo, including:

-- Outreach to target hospitals to create "Zingo advocates" on the

medical and nursing staff who will support formulary acceptance.

-- Design and impending launch of http://www.manageivpain.com, a website

that targets nurses with the goal of encouraging them to focus on the

management of IV pain.

-- Creation and promotion of RNvoice -- an organization of influential

nurses with a passion for reducing pediatric needlestick pain.

-- Creation of educational and selling tools for use by sales teams.

-- Maximizing public relations initiatives through multiple channels to

raise awareness of Zingo.

The company will re-affirm its prior guidance that Zingo will likely be priced in the range of $12 - $16 per unit.

Fosun Joint Venture To Facilitate Automated Manufacturing, Increased Capacity and Cost of Goods Improvements

Anesiva will also provide information about its joint venture with Wanbang Biopharma, a Fosun company, of XuZhou, China to establish additional manufacturing capacity for worldwide supply. The additional capacity will supplement the capacity provided by automated manufacturing operations currently being qualified in the US. The C
'/>"/>